B
Bull
Bull · 25%HOOK
$0.61
Scenario price
$0.840
-0.058 (-6.92%)At close
Loading chart…
- High
- 0.920
- Open
- 0.903
- VWAP
- 0.87
- Vol
- 589.35K
- Mkt Cap
- 64.33M
- Low
- 0.840
- Amount
- 510.89K
- EV/EBITDA, TTM
- 0.42
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics based on its arenavirus platform. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The Company has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1.
Valuation Metrics
The current forward P/E ratio for HOOKIPA Pharma Inc (HOOK) is -0.68, compared to its 5-year average forward P/E of -1.16.
Alphio AI Price Scenarios for HOOK
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
8.502-04NASDAQ.COMHOOKIPA Pharma Sells Immuno-Oncology Assets to NeoTrail Therapeutics
7.502-03seekingalphaHOOKIPA Pharma Sells Immuno-Oncology Assets to NeoTrail Therapeutics
8.502-03NewsfilterHOOKIPA Pharma Sells Immuno-Oncology Assets to NeoTrail
- 8.510-31Newsfilter
HOOKIPA Pharma Finalizes Sale of HBV and HIV Assets to Gilead
- 9.007-18SeekingAlpha
HOOKIPA Pharma to delist from Nasdaq and liquidate following Gilead asset sale
HOOK FAQ — answered by Alphio AI
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics based on its arenavirus platform. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The Company has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.